Literature DB >> 24626930

Complement is activated by IgG hexamers assembled at the cell surface.

Christoph A Diebolder1, Frank J Beurskens, Rob N de Jong, Roman I Koning, Kristin Strumane, Margaret A Lindorfer, Marleen Voorhorst, Deniz Ugurlar, Sara Rosati, Albert J R Heck, Jan G J van de Winkel, Ian A Wilson, Abraham J Koster, Ronald P Taylor, Erica Ollmann Saphire, Dennis R Burton, Janine Schuurman, Piet Gros, Paul W H I Parren.   

Abstract

Complement activation by antibodies bound to pathogens, tumors, and self antigens is a critical feature of natural immune defense, a number of disease processes, and immunotherapies. How antibodies activate the complement cascade, however, is poorly understood. We found that specific noncovalent interactions between Fc segments of immunoglobulin G (IgG) antibodies resulted in the formation of ordered antibody hexamers after antigen binding on cells. These hexamers recruited and activated C1, the first component of complement, thereby triggering the complement cascade. The interactions between neighboring Fc segments could be manipulated to block, reconstitute, and enhance complement activation and killing of target cells, using all four human IgG subclasses. We offer a general model for understanding antibody-mediated complement activation and the design of antibody therapeutics with enhanced efficacy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24626930      PMCID: PMC4250092          DOI: 10.1126/science.1248943

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  31 in total

1.  Convergent solutions to binding at a protein-protein interface.

Authors:  W L DeLano; M H Ultsch; A M de Vos; J A Wells
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 2.  C1q: structure, function, and receptors.

Authors:  U Kishore; K B Reid
Journal:  Immunopharmacology       Date:  2000-08

3.  Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authors:  Michel de Weers; Yu-Tzu Tai; Michael S van der Veer; Joost M Bakker; Tom Vink; Daniëlle C H Jacobs; Lukas A Oomen; Matthias Peipp; Thomas Valerius; Jerry W Slootstra; Tuna Mutis; Wim K Bleeker; Kenneth C Anderson; Henk M Lokhorst; Jan G J van de Winkel; Paul W H I Parren
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

4.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 5.  Complement and its role in innate and adaptive immune responses.

Authors:  Jason R Dunkelberger; Wen-Chao Song
Journal:  Cell Res       Date:  2009-12-15       Impact factor: 25.617

Review 6.  Antibody: the flexible adaptor molecule.

Authors:  D R Burton
Journal:  Trends Biochem Sci       Date:  1990-02       Impact factor: 13.807

7.  Antibody density on rat red cells determines the rate of activation of the complement component C1.

Authors:  N C Hughes-Jones; B D Gorick; J C Howard; A Feinstein
Journal:  Eur J Immunol       Date:  1985-10       Impact factor: 5.532

8.  Is IgM-like dislocation a common feature of antibody function?

Authors:  D R Burton
Journal:  Immunol Today       Date:  1986-06

9.  Activation of complement pathways by univalent antibody derivatives with intact Fc zones.

Authors:  H F Watts; V A Anderson; V M Cole; G T Stevenson
Journal:  Mol Immunol       Date:  1985-07       Impact factor: 4.407

10.  Quantitative immunology of immune hemolytic anemia. I. The fixation of C1 by autoimmune antibody and heterologous anti-IgG antibody.

Authors:  W F Rosse
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

View more
  265 in total

Review 1.  Complement activation, regulation, and molecular basis for complement-related diseases.

Authors:  Goran Bajic; Søren E Degn; Steffen Thiel; Gregers R Andersen
Journal:  EMBO J       Date:  2015-10-21       Impact factor: 11.598

Review 2.  Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant.

Authors:  Olivier Thaunat; Alice Koenig; Claire Leibler; Philippe Grimbert
Journal:  J Am Soc Nephrol       Date:  2016-02-12       Impact factor: 10.121

3.  Expression of factor H binding protein in meningococcal strains can vary at least 15-fold and is genetically determined.

Authors:  Massimiliano Biagini; Marco Spinsanti; Gabriella De Angelis; Sara Tomei; Ilaria Ferlenghi; Maria Scarselli; Fabio Rigat; Nicola Messuti; Alessia Biolchi; Alessandro Muzzi; Giulia Anderloni; Brunella Brunelli; Elena Cartocci; Francesca Buricchi; Chiara Tani; Maria Stella; Monica Moschioni; Elena Del Tordello; Annalisa Colaprico; Silvana Savino; Marzia M Giuliani; Isabel Delany; Mariagrazia Pizza; Paolo Costantino; Nathalie Norais; Rino Rappuoli; Vega Masignani
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-17       Impact factor: 11.205

4.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

5.  Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.

Authors:  Algirdas Grevys; Malin Bern; Stian Foss; Diane Bryant Bratlie; Anders Moen; Kristin Støen Gunnarsen; Audun Aase; Terje Einar Michaelsen; Inger Sandlie; Jan Terje Andersen
Journal:  J Immunol       Date:  2015-04-22       Impact factor: 5.422

6.  FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.

Authors:  Carole Seguin-Devaux; Jean-Marc Plesseria; Charlène Verschueren; Cécile Masquelier; Gilles Iserentant; Marie Fullana; Mihály Józsi; Jacques H M Cohen; Xavier Dervillez
Journal:  Mol Oncol       Date:  2019-09-30       Impact factor: 6.603

Review 7.  Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

Authors:  Pallawi Torka; Mathew Barth; Robert Ferdman; Francisco J Hernandez-Ilizaliturri
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

8.  Clinical utility of complement-dependent C3d assay in kidney recipients presenting with late allograft dysfunction.

Authors:  James H Lan; David Gjertson; Ying Zheng; Stephanie Clark; Elaine F Reed; Michael J Cecka
Journal:  Am J Transplant       Date:  2018-05-09       Impact factor: 8.086

9.  Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1.

Authors:  Ashish K Solanki; Yogendra S Rathore; Maulik D Badmalia; Reema R Dhoke; Samir K Nath; Deepak Nihalani
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

10.  Label-free detection of immune complexes with myeloid cells.

Authors:  Z Szittner; A E H Bentlage; P Rovero; P Migliorini; V Lóránd; J Prechl; G Vidarsson
Journal:  Clin Exp Immunol       Date:  2016-05-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.